TY - JOUR T1 - Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil JF - medRxiv DO - 10.1101/2021.05.10.21256644 SP - 2021.05.10.21256644 AU - Carlos A. Prete, Jr AU - Lewis F. Buss AU - Renata Buccheri AU - Claudia M. M. Abrahim AU - Tassila Salomon AU - Myuki A. E. Crispim AU - Marcio K. Oikawa AU - Eduard Grebe AU - Allyson G. da Costa AU - Nelson A. Fraiji AU - Maria do P. S. S. Carvalho AU - Charles Whittaker AU - Neal Alexander AU - Nuno R. Faria AU - Christopher Dye AU - VĂ­tor H. Nascimento AU - Michael P. Busch AU - Ester C. Sabino Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/16/2021.05.10.21256644.abstract N2 - Background The city of Manaus, north Brazil, was stricken by a second epidemic wave of SARS-CoV-2 despite high seroprevalence estimates, coinciding with the emergence of the Gamma (P.1) variant. Reinfections were postulated as a partial explanation for the second surge. However, accurate calculation of reinfection rates is difficult when stringent criteria as two time-separated RT-PCR tests and/or genome sequencing are required. To estimate the proportion of reinfections caused by the Gamma variant during the second wave in Manaus and the protection conferred by previous infection, we analyzed a cohort of repeat blood donors to identify anti-SARS-CoV-2 antibody boosting as a means to infer reinfection.Methods We tested serial blood samples from unvaccinated repeat blood donors in Manaus for the presence of anti-SARS-CoV-2 IgG antibody. Donors were required to have three or more donations and at least one donation during each epidemic wave. Donors were tested with two assays that display waning in early convalescence, enabling the detection of reinfection-induced boosting. The serial samples were used to divide donors into six groups defined based on the inferred sequence of infection and reinfection with non-Gamma and Gamma variants.Results From 3,655 repeat blood donors, 238 met all inclusion criteria, and 223 had enough residual sample volume to perform both serological assays. Using a strict serological definition of reinfection, we found 13.6% (95% CI 7.0% - 24.5%) of all presumed Gamma infections that were observed in 2021 were reinfections. If we also include cases of probable or possible reinfections, these percentages increase respectively to 22.7% (95% CI 14.3% - 34.2%) and 39.3% (95% CI 29.5% - 50.0%). Previous infection conferred a protection against reinfection of 85.3% (95% CI 71.3% - 92.7%), decreasing to respectively 72.5% (95% CI 54.7% - 83.6%) and 39.5% (95% CI 14.1% - 57.8%) if probable and possible reinfections are included.Conclusions Reinfection due to Gamma is common and may play a significant role in epidemics where Gamma is prevalent, highlighting the continued threat variants of concern pose even to settings previously hit by substantial epidemics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Itau Unibanco Todos pela Saude program and by a Medical Research Council-Sao Paulo Research Foundation (FAPESP) CADDE partnership award (MR/S0195/1 and FAPESP 18/14389-0) (caddecentre.org/). Wellcome Trust and Royal Society (N.R.F. Sir Henry Dale Fellowship: 204311/Z/16/Z); the National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study (REDS, now in its fourth phase, REDS-IV-P) for providing the blood donor demographic data for analysis (grant HHSN268201100007I). CAPJ was supported by FAPESP (2019/21858-0), Fundacao Faculdade de Medicina and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brasil (CAPES), Finance Code 001. VHN was supported by CNPq (304714/2018-6).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the Brazilian national research ethics committee, CONEP CAAE - 397909020.9.1001.0009All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized individual-level data of the 238 selected blood donors along with a data dictionary is available at https://github.com/carlosprete/reinfection_manaus. Data related to all repeat blood donors can be shared upon request. ER -